. ' 19 Claims, No_ Drawings Communications, vol. 122, No. 2, 1984 ,'Jul. 31, 1984 . Tuhy, Peter M. and Powers, James C.: "Inhibition of Human Leukocyte Elastase by Peptide Chloromethyl Ketones", Feb. 1975. Powers, James C., Gupton, B. relates to novel synthetic routes to synthesize the pepti dyl carbamates of the invention and to methods of in hibiting the enzyme elastase with the compounds of the invention.
BACKGROUND ART
Proteinases from polymorphonuclear leukocytes and macrophages, especially elastases (human leukocyte elastase and cathepsin G), appear to be responsible for the chronic tissue destruction associated with in?amma tion, arthritis and emphysema. During infection or in ?ammation the normal lung is protected from proteo lytic digestion by the protease inhibitor al-antiryspin.
The protective mechanism appears to be non-operative in individuals with an a1-antitrypsin elastase inhibitors capable of replacing al-antitrypsin therefore appear to be useful in the treatment of pulmonary emphysema and related diseases.
Several types of elastase inhibitors have been re ported in the literature. These include peptide chloro methyl ketones as described in "Inhibition of Human Leukocyte El'astase by Peptide Chloromethyl Ke tones", P. M. Tuhy and J. C. Powers, FEBS Letters, 50, 359-61 (1975) Thus, this invention provides certain novel substi tuted peptidyl carbamate compounds, pharmaceutical compositions containing these compounds, and meth ods for using these pharmaceutical compositions in the selective inhibition of the enzyme elastase without af fecting similar serine dependent proteases, e.g., trypsin and chymotrypsin.
It is known from the art that proteases from polymor phonuclear leukocytes and macrophages, especially elastases (human leukocyte HL elastase and cathepsin G) appear to be responsible for the chronic tissue de struction associated with in?ammation, arthritis and emphysema. During infection or in?ammation, the nor mal lung is protected from proteolytic digestion by the protease inhibitor, al-antitrypsin. This protective mech anism appears to be non-operative in individuals with an ai-antitrypsin de?ciency due to genetic or other causes.
Synthetic elastase inhibitors capable of replacing a1 antitrypsin are therefore useful in the treatment of pul monary emphysema and related diseases.
According to the present invention, a class of com pounds containing the carbamate functionality and The mechanism of the invention appears to take ad vantage of the fact that these carbamate esters will react with proteases and esterases at the carbonyl carbon by losing the alkoxy portion and transferring the car bamylating moiety to the active site of the enzyme. Acylation will then lead to recovery of enzymatic ac tivity.
The present invention provides a series of carbamate compounds which are active in accordance with the above proposals as elastase enzyme inhibitors. These novel compounds are carbamates substituted by oligo peptides which are selected from the group consisting of a compound of the formula
and a compound of the formula In a more preferred and detailed embodiment the compound of the invention is selected from the group consisting of The 'peptidyl carbamate inhibitors of the invention selectively inhibit the enzyme elastase, e.g., human leu kocy'te elastase (HLE) and porcine pancreatic elastase (PPE), with inhibitor dissociation constants ranging from 3X l0-6M to 2X l0-9M.
All the peptidyl carbamate inhibitors of the invention have been found to selectively inhibit the enzyme elas tase without inhibiting other enzymes such as trypsin or chymotrypsin, amont other enzymes.
The peptidyl carbamate inhibitors of the invention are desmosine-like derivatives incorporating L-lysine or L-ornithine residues at the P3 or P4 regions of their structures. These features simulate the protruding chains of desrnosine cross-linking units in mature elas tin.
The present compounds are synthesized in general by methods which are improvements over the method described in US. Pat. No. 4,643,991 to Digenis et al, the entire content of which is incorporated herein by refer ence. The synthetic approach of this invention involves the coupling of the P6-P3 moieties of the inhibitor mole cules with the P2-P1 moieties as depicted in Scheme 1 herebelow. The synthesis of methoxysuccinyl-alanine aminoacid dipeptides of the invention is depicted in Scheme 2 herebelow As previously indicated the aminoacid residue could be omithine or lysine with carbobenzoxy or benzoyl at their terminal amino functions (Ni). Examples of these compounds are represented by the structures of Com pounds 12, 15 and 18 which are products obtained in accordance with the procedure described in Scheme 3.
The coupling of other inhibitor compounds similar to compounds 7 and 9 shown in Scheme 2 with intermedi ate compound 22 appearing in Scheme 4 results in the synthesis of the compounds 48-51 shown in Table 2 below. 13 14 Table 1 II + herebelow. Pam-N C_CH=N=NT.
(3) RC1 (anhydrous), 5' C. 'n50 mixture of two inhibitors, each contributing 3.8 X 10-7 M.
Extremely highly potent inhibitors of the enzyme pound PC6. The synthesis of these compounds are de elastase are obtained by replacing the p-nitrophenyl picted in Scheme 6 below.
Scheme6
Synthesis of PCS and PC6 Preparation of thiocar' portion.
The conditions for conducting the various steps en compassed by these methods are known in the art and to an artisan in the ?eld.
As pointed out above, the compounds of the inven tion may be' employed as speci?c active site directed inhibitors of the enzyme, elastase. For this purpose, the compounds are preferably combined with a pharmaceu tically acceptablecarrier for administration by injection or in the oral form. Conventional adjuvant and carriers may be employed in combination with about 0.001 to 2.0 weight percent of the active compound. The com pounds may be administered to animals or humans at about 10 mg/kg, preferably an average amount of about 6 mg/kg.
The following examples illustrate preferred embodi ments of the invention but the invention is not consid ered to be limited thereto. A solution of 3-carbomethoxypropionyl chloride (5 g, 33.2 mmoles) and N-hydroxysuccinimide (3.8 g, 33.2 mmoles) in ethyl acetate (60 ml) was cooled to 5' C.
While stirring, triethylamine (4.3 g, 33.2 mmoles) was slowly added to the cooled solution over a 15 min inter val. The mixture was allowed to equilibrate to room temperature (22' C.) and react for an additional 3 h. The formed triethylamine salt was ?ltered, washed with ethyl acetate and the ?ltrate evaporated under vacuum.
The powderwas recrystallized from ethyl acetate/hex ane to give 5.5 g (24.2 mmoles) (72% yield) of white To an ice cooled suspension of the activated ester _ 2(3.6 g, 16 mmoles) and L-alanine t-butyl ester (2.3 g, 16 mmoles) in THF (50 mL), triethylamine (2.0 g, 16 mmoles) in THF (1 mL) was added dropwise. The progress of the reaction was monitored by TLC (10% methanol in chloroform) and stirred at 5' C. for 3.5 h. The precipitate was ?ltered under vacuum and washed with ethyl acetate. The residual oil, containing the product, was chromatographed using 40 g of silica gel column (2X 50 cm). Impurities were eliminated by ?rst passing 50 mL of methylene chloride and subsequently compound 3 was eluted with 2%. methanol in methy lene chloride. Upon evaporation of the eluent solvent under reduced pressure the product was obtained. The latter was then crystallized from ethyl acetate/pe troleum ether to give 2.9 g (11.3 mmoles) (71% yield) of a crystalline powder vmp 9l°-92' C. lH-NMR (CDCl3) The t-butyl ester 3 was hydrolyzed by either of the following methods in good yield.
Procedure A: Formic acid (98%)(l.5 mL) was added to an ice cooled solution of 3 (1.0 g, 3.9 mmoles) dissolved in ethyl acetate (10 mL). Hydrogen chloride gas was slowly bubbled through the cooled solution in two short (30 s) intervals 10 min apart. The solution was allowed to warm to room temperature and stirred for 2 h. The volatile liquids were evaporated in vacuo. The residue, containing the product, was chromatographed on 15 g of silica gel column (1 X25 cm). The product 4 'was eluted with 4% methanol in methylene chloride. Upon evaporation of the eluent solvent under reduced pressure 0.77 g (3.8 mmoles) (98% yield) of a transpar ent oil was obtained.
Procedure B: A solution of 3 (1.0 g, 3.9 mmoles) in glacial acetic acid (5 mL) at room temperature was slowly diluted with 30% HBr in acetic acid (5 mL) and stirred for 30 min. The reaction was stopped by the addition of ice water (15 mL) and the ?ne suspension was extracted with methylene chloride (5 X 25 mL). This compound was prepared from N¢»benioyl-L lysine (not the phenacyl ester) according to an analo gous procedure to that described for 6, with the follow ing changes: the solvent was changed to DMF, the reaction time was extended to 24 h and the eluting sol vent was changed to 8% methanol in chloroform. Upon evaporation of the eluent solvent under reduced pres sure 0.37 _g (0.85' mrnoles) (47% yield) of a transparent oil was obtained. 1H-NMR (CDC13) 2H, r, app. dd, J, J, ~=2Hz); 7.43(1Hj, app. dd, Jji=8HZ, Jjk=2HZ); 7.86(2Hk, k', app. To a mixture of Npcarbobenzoxylysine phenacyl ester hydrochloride (35) (0.7 g, 1.7 mrnoles) and the above N-hydroxysuccinimide ester in cooled THF (7 mL), triethylamine (0.17 g, 1.7 mrnoles) in THF (0.5 mL) was added dropwise. A solution was observed for a short period of time before a precipitate was formed. The progress of the reaction was monitored by TLC (10% methanol in chloroform). Upon completion of the reaction (4 h), the formed triethylamine salt was ?l tered, washed with ethyl acetate and the ?ltrate evapo rated under vacuum. The residue, containing the prod uct, was chromatographed on 15 g of silica gel column (1 X25 cm). Impurities were eliminated by ?rst passing 50 mL of methylene chloride and subsequently the compound was eluted with 2% methanol in methylene chloride. Upon evaporation of the eluent solvent under reduced pressure a hygroscopic product was obtained. The latter was then recrystallized from ethyl acetate/ diethylether to give 0.8 g (1.3 mmoles) (84% yield) of a crystalline powder, mp 1l4°-1 16' C. lH-NMR(CDC13,) EX. 6 . Na-Methoxysuccinylalanyl-Ne-carbobenzoxylysine (.7) Small portions of zinc metal (total 2 g) were added over a l h period to a solution of phenacyl ester 6 (0.6 g, 1.1 mmoles) in glacial acetic acid (10 mL). The title compound was prepared from Na-carboben zoxy-L-ornithine phenacyl ester hydrochloride follow ing an analogous procedure to that described for 6. The This compound was prepared from 10 according to an analogous procedure to that described for 14. The product (1 l) was crystallized from ethyl acetate/hexane to give 1.7 g (3.3 mmoles) (87% yield) of a white crys talline powder mp l33°-l35° C. 1I-I-NMR (CDC13) The title compound was prepared from 15 and 22 diastereomer) following a procedure analogous to that described for
